KRAS and non-small cell lung carcinoma: Such mutations have also been linked with resistance to cetuximab and panitumumab for CRC patients, and erlotinib and gefitinib for NSCLC patients, rendering anti-EGFR treatments relatively ineffective among KRAS(+) patients (Bournet et al., 2016; Tan & Du, 2012; Pao et al., 2005).